Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT06086990 Recruiting - Cancer Clinical Trials

Effects of Telemonitoring in Quality of Life Amongst Cancer Patients

EQUALITE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This interventional study aims to explore the potential of a smartphone app, Contigo, in enhancing the quality of life for patients with various cancers compared to standard care. The investigators will asses effects on quality of life, depressive symptoms, and appointment adherence.

NCT ID: NCT06083324 Recruiting - Cancer Clinical Trials

EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer

EXERT-C
Start date: February 3, 2023
Phase:
Study type: Observational [Patient Registry]

This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer.

NCT ID: NCT06081452 Recruiting - Cancer Clinical Trials

Public Survey on Breath Testing for Health and Disease

Start date: June 17, 2023
Phase:
Study type: Observational

A brief survey for the public to determine interest in health surveillance and disease detection

NCT ID: NCT06077123 Recruiting - Cancer Clinical Trials

Telemonitoring Platforms and Chemotherapy-Associated Toxicity

DETECT
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The primary objective of this trial is to evaluate the impact of a telemonitoring platform on patient satisfaction with care amongst adult cancer patients receiving chemotherapy. The key questions it seeks to address revolve around the potential improvements in both quality of life and satisfaction with healthcare. Participants in the trial will be provided with a specialized application developed by a team of experienced oncology professionals. Their quality of life and healthcare experience will be compared with that of the control group, who will only receive the standard in-person check-ups established by their healthcare team.

NCT ID: NCT06077110 Not yet recruiting - Cancer Clinical Trials

P-OMICs-flow: Integrating Precision Oncology Into Clinical Programs

P-OMICs-flow
Start date: October 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to drive integration of precision medicine into routine oncology healthcare. It is hoped that this research will not only optimise the newly established P-OMICs-flow model of care within The Prince of Wales Hospital, but also prime it for use within other health care sites. The multidisciplinary team will work to achieve the following three objectives: 1. Co-design a clinic, implementation platform and suite of outcome measures to optimise P-OMICs-flow (Phase 1) 2. Test the implementation, service-, clinical, and cost-effectiveness of P-OMICs-flow (Phase 2) 3. Develop and pilot test a P-OMICs-flow scale-up model and toolkit (Phase 3) A mixed-methods approach will be used to develop and evaluate an implementation platform to support the integration of precision medicine into the routine oncology setting at a single hospital site. In the first study phase, interviews and focus-groups will be used to develop the implementation platform, which involves a co-designed model of care supported by a Learning Health System. A Type II Hybrid effectiveness-implementation trial design will then be used to test the implementation, clinical, and cost-effectiveness of the P-OMICs-flow model of care (phase 2). A combination of patient surveys and interviews will be used to measure patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs); stakeholder and patient interviews, surveys and focus-groups will be used to measure implementation outcomes; and cost data will be collected to inform an economic evaluation. These data will be collected at various stages of implementation to evaluate the effectiveness of the P-OMICs-flow model of care over time. In the final study phase (phase 3), a scale-up model will be developed to support implementation of the new model of care across a wider range of clinical contexts. (Phase 3 will be detailed in a separate ethics amendment) It is hoped that this research will not only optimise the newly established model of care within The Prince of Wales Hospital, but also prime it for use within other health care sites.

NCT ID: NCT06074445 Completed - Cancer Clinical Trials

Caring for the Sexual Health and Wellbeing of Cancer Survivors and Their Intimate Partners: An Anonymous Survey

Start date: August 23, 2022
Phase:
Study type: Observational

The aim of this survey study is to provide broad information as reported by cancer survivors and their intimate partners about both their sexual health and their experiences of care from the United Kingdom hospital cancer team, including their perspectives on factors that may hinder or help care. This information will be analysed and used to inform the questions asked in a separate, subsequent, qualitative study.

NCT ID: NCT06072287 Recruiting - Obesity Clinical Trials

The Living With a Long-Term Condition Study

LTC
Start date: June 28, 2023
Phase:
Study type: Observational

Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs). Being able to measure whether psychological distress is related to living with a LTC would allow researchers and clinicians to provide interventions specifically tailored to the challenges of living with a LTC and therefore provide the most appropriate support for these patients. Such a measure would also be useful in research to identify the presence of illness-related distress in different patient groups. This project will therefore create a new measure of illness-related distress that has applications for both research and clinical practice. This will involve the psychometric validation of the new illness-related distress measure to test how valid and reliable the measure is. The aim of the project is to provide initial validation of the Illness Related Distress Scale in a community sample, recruited through online platforms. The objective of the study is to gather initial validity and reliability data for the scale.

NCT ID: NCT06071650 Recruiting - Cancer Clinical Trials

Assessment, Monitoring and Optimisation of Prehabilitation Patients Using Wearable Fitness Trackers

Start date: February 27, 2023
Phase: N/A
Study type: Interventional

Prehabilitation is the use of exercise prior to surgery to improve peoples' fitness, which leads to improved outcomes of surgery. This service is now being run remotely, however, there is little existing evidence to support the best practice for this. Currently, baseline fitness is assessed remotely using either a sit to stand test or a step test. Once completed people are prescribed regular exercises and asked to exercise to a level of intensity using a measure called Rating of Perceived Exertion (RPE). However, these measurements may not be reliable. We are carrying out a study to assess if another waking test (modified Rockport test) and asking patients to exercise to a target heart rate are better measures of assessing baseline fitness and exercise intensity. All participants will receive weekly telephone calls to check their progress and be provided with a wrist worn fitness tracker (Fitbit). Participants will be randomised to one of two groups. The only difference between the groups will be the way the exercise is prescribed. In one group participants will be asked to complete the exercises to an exercise level they find "somewhat hard". The other group will be asked to complete the exercises to maintain a set heart rate. All participants will be asked to complete an activity log (submitted weekly) as an online form. A small group of people (maximum 10) will be asked if they would like to complete an in-person baseline fitness assessment also, this is optional. This study runs for up to eight weeks with participation ending after eight weeks or at the time of surgery, whichever is sooner. In the final week of participation, participants will be asked to complete an online questionnaire about their experience of using a wearable fitness tracker during the prehabilitation programme.

NCT ID: NCT06065592 Recruiting - Breast Cancer Clinical Trials

Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms

CAT_PB
Start date: February 1, 2019
Phase: Phase 1
Study type: Interventional

This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system. The roles of immune checkpoints, inflammatory and angiogenesis factors, as well as circulating immune cells will be elucidated. Additionally, our investigation extends to the exploration of long non-coding RNAs (LncRNAs) and genes associated with the coagulation vascular system. Initially, these aspects will be evaluated in the context of colorectal cancer, with the intention to expand our research to other solid tumors. The identification of these biomarkers and genetic factors holds the potential to revolutionize therapeutic approaches for patients with cancer-associated thromboembolism, shedding light on their chemotherapy resistance. The effectiveness of combining immunotherapy with targeted inhibitors like Palbociclib and anticoagulants such as Rivaroxaban, among other potential interventions, will be assessed. This study aims to make significant contributions to the understanding of these critical aspects, ultimately leading to the development of more effective treatment strategies for cancer patients.

NCT ID: NCT06061874 Recruiting - Cancer Clinical Trials

Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

FAPeCa
Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein). The aim of the study is to assess the accuracy of Ga68-FAPI-46 PET/CT for preoperative assessment of peritoneal carcinomatosis in colorectal and ovarian cancer.